Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (PYCR1)
- Development stage
- Preclinical
- Lead developer
- Vrije Universiteit Brussel
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA (PYCR1) is a small interfering RNA designed to silence the expression of Pyrroline-5-carboxylate reductase 1 (PYCR1), an enzyme critical for the conversion of glutamate to proline. In the context of multiple myeloma (MM), PYCR1 is upregulated in both tumor cells and the bone marrow microenvironment (stroma), particularly under hypoxic conditions. By inhibiting PYCR1, this siRNA aims to disrupt proline metabolism, which is essential for tumor cell proliferation and the structural integrity of the extracellular matrix (ECM). Preclinical studies have demonstrated that PYCR1 knockdown in stromal cells reduces their protective effect on myeloma cells and limits tumor growth when combined with standard-of-care agents like bortezomib.
- Other names
- PYCR1 siRNAPYCR-1 siRNAPYCR 1 siRNAsiRNA targeting PYCR1
02
Targets
PYCR1/PYCR2 (Pyrroline-5-carboxylate reductases 1/2)
Beyond the preview
Go deeper on siRNA (PYCR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (PYCR1).